Robert Azelby's Net Worth
$7.95 Million
Who is Robert Azelby?
Robert Azelby has an estimated net worth of $7.95 Million. This is based on reported shares across multiple companies, which include Cascadian Therapeutics, Inc., IMMUNOMEDICS INC, ALDER BIOPHARMACEUTICALS INC, Eliem Therapeutics, Inc., Clovis Oncology, Inc., Juno Therapeutics, Inc., and CHINOOK THERAPEUTICS, INC..
SEC CIK
Robert Azelby's CIK is 0001656998
Past Insider Trading and Trends
2018 was Robert Azelby's most active year for acquiring shares with 9 total transactions. Robert Azelby's most active month to acquire stocks was the month of January. 2018 was Robert Azelby's most active year for disposing of shares, totalling 23 transactions. Robert Azelby's most active month to dispose stocks was the month of February. 2018 saw Robert Azelby paying a total of $6,215,553.80 for 1,190,821 shares, this is the most they've acquired in one year. In 2018 Robert Azelby cashed out on 627,501 shares for a total of $12,442,231.10, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Cascadian Therapeutics, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 9
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 9
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 3
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
IMMUNOMEDICS INC No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 23
| |||
Form 4
|
∞
| 3.72K |
—
|
—
| 3.72K |
Jun 18
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 26
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
ALDER BIOPHARMACEUTICALS INC No price found
President and CEO
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 22
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 23
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 6
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 13
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Eliem Therapeutics, Inc. (ELYM) Snapshot price: $2.62
President & CEO
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 31
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 27
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Clovis Oncology, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 10
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 4
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 6
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 11
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||